Recent Updates
Recently added Catalysts
MNPR Positive Sentiment Score: 70/100

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Tuesday, October 10, 2023 1 min read
Key Takeaway: Monopar Therapeutics Inc. will present at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023. Andrew J. Cittadine, the Chief Operating Officer, will showcase the company's efforts and pipeline in cancer treatment. Monopar is focused on delivering innovative therapies, including camsirubicin and various antibody treatments, aimed at advanced cancers. The event will be held at The Yale Club in New York City.

Market Sentiment Analysis

POSITIVE FACTORS

  • Monopar is actively participating in a healthcare conference, increasing visibility.
  • The company is focused on developing innovative treatments for cancer patients.
  • Showcases engagement with the investment community, potentially attracting interest and support.

Full Press Release Details

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference.
Presentation Details:
Date: October 12, 2023
Time: 12:15 p.m. (ET)
Location: The Yale Club, New York City, New York
https://www.roth.com/conferences/upcoming-conferences
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.
Monopar Therapeutics Inc.
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Frequently Asked Questions

When is Monopar Therapeutics presenting at the conference?

Monopar will present on October 12, 2023.

Where will the Roth MKM conference take place?

The conference will be at The Yale Club in New York City.

What is Monopar Therapeutics focused on?

Monopar focuses on developing innovative cancer treatments.

What is camsirubicin used for?

Camsirubicin is in Phase 1b for treating advanced soft tissue sarcoma.

How can I get more information about Monopar?

Visit Monopar's website at www.monopartx.com for more details.

Tags: MNPR Viatris Investor Conferences Healthcare Monopar Therapeutics cancer treatments healthcare conference Roth MKM
Last updated: Oct 10, 2023